Navigation Links
Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
Date:11/16/2011

PARSIPPANY, N.J., Nov. 16, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its public offering of 7,000,000 shares of its common stock at a price of $6.50 per share. All of the 7,000,000 shares are newly issued and are being offered by Pacira, with expected net proceeds to Pacira of approximately $42.3 million after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Pacira has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares to cover over-allotments, if any.

Barclays Capital Inc. and Jefferies & Company, Inc. are acting as joint book-running managers for the offering. Piper Jaffray & Co., Wedbush PacGrow Life Sciences and Brean Murray, Carret & Co. are acting as co-managers for the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. A copy of the final prospectus for this offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by calling 1-888-603-5847 or by emailing Barclaysprospectus@broadridge.com. A copy of the final prospectus may also be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, telephone: (877) 547-6340, email
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at 165 ... the first in Loudoun County to receive ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian of ... Taylor , are avid scuba divers. "As altitude skiers and hikers, ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... March 8, 2012 , Quality of Life ... available treatment fails in two thirds of patients ... Pevion Biotech AG today announced results from a large, ... vulvovaginal candidiasis (RVVC) patients. It is the first time that ...
... Inc. (Nasdaq: BIOD ) today announced that ... will present a corporate update at the ROTH 24th Annual ... 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). ... Conference will be held March 11-14, 2012, at the ...
Cached Medicine Technology:Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 2Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 3Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 4
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... show signs of chronic inflammation in non-cancerous prostate tissue ... prostate cancer than those with no inflammation, according to ... the Johns Hopkins Kimmel Cancer Center. , The link ... men with so-called high-grade prostate cancer those with ... the presence of the most aggressive and rapidly growing ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... of DNA testing and genetic profiling is proving many skeptics wrong. ... tests outweigh consumers, privacy concerns. From dating, through genealogy, to ... health and lifestyle decisions is gaining acceptance. , ... ...
... OBESE MAY CARRY ASTHMA TRAIT , A new study ... carry a specific trait or phenotype that causes them ... not obese with asthma. Researchers from Quebec, Canada compared ... counts, symptom perceptions, BMI/waist circumference, and waist-to-hip ratio of ...
... Aug. 4 The Kansas Health Policy,Authority (KHPA) has ... enable the agency to analyze the cost and effectiveness ... of a data repository and a data analytic,interface (DAI) ... several,state programs. Andy Allison, KHPA,s deputy director and Medicaid ...
... HILL In the budding field of nanotechnology, scientists already ... the University of North Carolina at Chapel Hill have shown ... lead to new and more effective methods for treating cancer ... and obesity. , A team of researchers led by Joseph ...
... to start or continue smoking, researchers say , , MONDAY, Aug. ... appears to have a stronger effect in people who smoke, ... heart attack patients after the attack. It inhibits formation of ... 259 people given Plavix because of coronary conditions found that ...
... 2008 Revenue Increases 36% to $16.9 Million ... Sets Quarterly Record ... MINNEAPOLIS, Aug. 4 ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... results for the,second quarter ended June 28, 2008. Revenue for the ...
Cached Medicine News:Health News:DNA Testing and Genetic Profiles Help Avoid Broken Hearts Polls Reveal 2Health News:DNA Testing and Genetic Profiles Help Avoid Broken Hearts Polls Reveal 3Health News:Chest Journal: August news briefs 2Health News:Kansas Health Policy Authority Awards Thomson Reuters Contract for Health Care Data Integration and Analysis Initiative 2Health News:Kansas Health Policy Authority Awards Thomson Reuters Contract for Health Care Data Integration and Analysis Initiative 3Health News:UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies 2Health News:UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies 3Health News:Blood-Thinner Plavix Works Harder in Smokers 2Health News:ATS Medical Announces Second Quarter Results 2Health News:ATS Medical Announces Second Quarter Results 3Health News:ATS Medical Announces Second Quarter Results 4Health News:ATS Medical Announces Second Quarter Results 5Health News:ATS Medical Announces Second Quarter Results 6Health News:ATS Medical Announces Second Quarter Results 7Health News:ATS Medical Announces Second Quarter Results 8Health News:ATS Medical Announces Second Quarter Results 9Health News:ATS Medical Announces Second Quarter Results 10
... Tosoh Corporation launched the first generation HPLC ... HPLC/723Ghb brought a new level of automation ... forefront of diabetes testing in Japan. Now ... system, the G7 offers advanced automation; stable ...
... , Monoclonal antibody method for HbA1c ... study shows 99% agreement with the HPLC ... on a CV of 2.6%* means ... Standardization Program (NGSP) certified method, as recommended ...
... Maximize your laboratorys ... and enhanced automated workflow ... high-throughput automated workstation now ... and immunoassay with specimen ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: